Recently, the Shanghai Bone Tumor Institute (SBTI) was approved as a collaborating center by ICMRS and on May 13, 2016, the SBTI-ICMRS Collaborating Center for Bone Tumor Research was officially established in Shanghai. Dr. James Wang, ICMRS President, Dr. Tingting Tang, ICMRS President-Elect, and Dr. Bin Li, Chair of China Development Committee, were present at the ceremony. Dr. Wang delivered an opening remark.
Briefly, on behalf of ICMRS, Dr. Wang expressed his pride and honor in establishing the SBTI-ICMRS Collaborative Research Center. He commended the SBTI leadership for putting together a successful center application, and appreciated their interest in working with ICMRS to promote bone tumor research. Dr. Wang reiterated that ICMRS will do its part in helping SBTI in preparing and submitting manuscripts for publication in peer-reviewed journals with high impact, in preparing grant applications and also explore joint grant application options. He assured that ICMRS will also support local educational activities, such as workshops and conferences, and provide platforms to train center staff members in ICMRS member institutions overseas.
SBTI was founded in 2013 and is directed by Dr. Zhendong Cai. SBTI is a relatively young institution and aims to develop a strong research program in bone cancer biomarker, genome sequencing and related areas. It is anticipated that building on the strong ties with ICMRS, the SBTI-ICMRS Collaborating Center will soon grow into a leading center in clinical and basic research in bone tumor in China.To date, there are 21 Centers collaborating with ICMRS at China.